APP and Alzheimer disease: It has previously been observed using an AD plaque-developing mouse model (APP/PS1) that TXNIP protein levels were increased in frontal cortex and hippocampus of 9- and 12-month-old mice compared to wild-type non-transgenic mice, while TRX levels were unchanged [15].